📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
128 announcements match the current filters (relevance ≥ 5).
Mankind Pharma Assigned CARE AA+; Stable Rating for ₹1,000 Crore Bank Facilities
Mankind Pharma Limited has received new credit ratings from CARE Ratings Limited for its bank facilities totaling ₹1,000 crore. The agency assigned a 'CARE AA+; Stable' rating for long-term facilities and 'CARE A1+' for short-term facilities. These high investment-grade ratings underscore the company's robust credit profile and strong liquidity position. Such ratings typically allow the company to access capital at competitive interest rates and reflect a low risk of default.
Key Highlights
CARE Ratings assigned 'CARE AA+; Stable' for long-term bank facilities.
Short-term bank facilities were assigned the highest possible rating of 'CARE A1+'.
The total value of the bank facilities covered under this rating assignment is ₹1,000 crore.
The ratings were assigned at the request of the company to assess its creditworthiness.
👀 What to Watch
The high credit rating confirms Mankind Pharma's financial stability and strong balance sheet. Investors should view this as a positive indicator of the company's ability to manage debt and fund future growth at optimal costs.
Bank of India Q4 FY26 Provisional: Global Business Grows 14.5% YoY to ₹16.98 Lakh Cr
Bank of India reported strong provisional growth for the fiscal year ending March 31, 2026, with total global business reaching ₹16.98 lakh crore. Global advances grew by 15.69% YoY, significantly outperforming global deposit growth of 13.58% YoY. A key driver was the domestic RAM (Retail, Agri, MSME) segment, which surged by 18.63% YoY to ₹3.83 lakh crore. These figures indicate robust credit demand and healthy balance sheet expansion for the public sector lender.
Key Highlights
Global Business increased 14.53% YoY to ₹16,98,026 crore as of March 31, 2026
Gross Advances (Global) rose 15.69% YoY to ₹7,70,566 crore, showing strong credit momentum
Domestic RAM Advances grew significantly by 18.63% YoY to ₹3,82,796 crore
Global Deposits stood at ₹9,27,460 crore, marking a 13.58% YoY growth
Domestic Gross Advances grew 15.95% YoY to ₹6,53,441 crore
👀 What to Watch
The strong growth in high-yield RAM advances and overall credit suggests improving profitability; investors should monitor the upcoming full results for Net Interest Margin (NIM) and asset quality trends.
JNK India Bags Major Order Worth ₹300-600 Crore for Refinery Project
JNK India Limited has secured a 'Major' order from its promoter entity, JNK Global Co., Ltd., Korea. The contract involves providing support services and supplies for a Cracker Furnace Package for a refinery project located in India. Valued between ₹300 crore and ₹600 crore, this order significantly boosts the company's order book. The project is slated for completion by February 2, 2028, ensuring long-term revenue visibility.
Key Highlights
Order value classified as 'Major', ranging between ₹300 crore and ₹600 crore
Contract awarded by promoter JNK Global Co., Ltd., Korea, for a domestic refinery project
Project execution timeline set for completion by February 2, 2028
Transaction confirmed as a related party contract conducted at an arm's length basis
👀 What to Watch
This order win provides strong revenue visibility for the next two fiscal years; investors should monitor execution milestones and potential margin impacts from this related-party transaction.
Mankind Pharma Acquires Roche's Rivotril Brand to Strengthen CNS Portfolio in India
Mankind Pharma has acquired the exclusive rights to manufacture, market, and distribute the innovator brand Rivotril (clonazepam) from Roche for the Indian market. This acquisition is a strategic move to bolster Mankind's presence in the Central Nervous System (CNS) and chronic therapy segments, which are high-growth areas. The company plans to leverage its massive distribution network of over 17,700 professionals and reach of 5 lakh doctors to scale the brand. This deal follows Mankind's recent focus on specialty segments and high-margin chronic therapies to diversify its portfolio.
Key Highlights
Acquired exclusive rights for the innovator brand Rivotril from Roche for the Indian market
Strengthens strategic focus on chronic therapies and the Central Nervous System (CNS) segment
Leverages a distribution network of 17,700+ professionals and 32 manufacturing facilities
Aims to utilize a reach of over 5 lakh doctors to drive penetration in urban and semi-urban markets
Creates a platform for future expansion through potential line extensions in the CNS category
👀 What to Watch
Investors should view this as a positive development as it enhances Mankind's portfolio with a high-recall innovator brand in the chronic segment. Monitor the company's execution in scaling this brand and its impact on overall margins in the coming quarters.
JNK India Appoints Anand Agarwal as Interim CFO and Key Managerial Personnel
JNK India Limited has appointed Mr. Anand Agarwal as its Interim Chief Financial Officer and Key Managerial Personnel, effective March 12, 2026. Mr. Agarwal is a Chartered Accountant with 20 years of experience in finance leadership across the EPC, infrastructure, and oil & gas sectors. He will hold the position until a permanent CFO is appointed by the Board. This move ensures continuity in the company's financial governance and regulatory compliance following the board meeting held on March 12, 2026.
Key Highlights
Mr. Anand Agarwal appointed as Interim CFO and KMP effective March 12, 2026.
Brings 20 years of experience from senior roles at companies like Kalpataru Projects International Limited.
Expertise includes project finance, treasury, debt structuring, and ERP transformation.
Authorized by the Board to determine materiality of events for SEBI disclosures.
The appointment follows a Board Meeting concluded within 26 minutes on March 12, 2026.
👀 What to Watch
Investors should view this as a routine management transition and monitor for the announcement of a permanent CFO appointment. The interim choice appears well-qualified with significant industry experience, suggesting minimal disruption to financial operations.
Fitch Upgrades Bank of India's Viability Rating to 'bb'; Affirms IDR at 'BBB-'
Fitch Ratings has upgraded Bank of India's (BOI) Viability Rating (VR) to 'bb' from 'bb-', signaling a stronger intrinsic financial profile. The bank's Long-Term Issuer Default Rating (IDR) remains affirmed at 'BBB-' with a Stable Outlook, reflecting high expectations of government support. Key financial metrics have shown marked improvement, with the impaired-loan ratio dropping to 2.3% in 9MFY26 and credit costs reducing to 0.4%. The bank maintains a healthy capital cushion with a CET1 ratio of 15.3%, well above regulatory requirements.
Key Highlights
Viability Rating (VR) upgraded to 'bb' from 'bb-' reflecting improved risk profile and asset quality.
Impaired-loan ratio improved significantly to 2.3% in 9MFY26 from 3.3% in the previous year.
Common Equity Tier 1 (CET1) ratio strengthened to 15.3%, providing a 400bp cushion over the rating threshold.
Credit costs declined to 0.4% of loans in 9MFY26, down from 1.0% in FY25.
Fitch affirmed the Long-Term Issuer Default Rating at 'BBB-' with a Stable Outlook.
👀 What to Watch
The upgrade in the Viability Rating confirms the bank's improving fundamental health and better risk management. Investors should monitor if the bank can sustain these asset quality improvements while managing loan growth in a competitive environment.
Mankind Pharma Credit Ratings Reaffirmed by ICRA for ₹6,250 Crore Debt Instruments
ICRA Limited has reaffirmed the credit ratings for Mankind Pharma's debt instruments totaling ₹6,250 crore. The Non-Convertible Debentures (NCDs) worth ₹5,000 crore maintained an [ICRA]AA+/Stable rating. Additionally, long-term and short-term fund-based limits of ₹1,250 crore were reaffirmed at [ICRA]AA+ (Stable) and [ICRA]A1+ respectively. This reaffirmation reflects the company's strong financial profile and continued creditworthiness in the pharmaceutical sector.
Key Highlights
ICRA reaffirmed [ICRA]AA+/Stable rating for ₹5,000 crore Non-Convertible Debentures.
Fund-based limits of ₹1,250 crore reaffirmed at [ICRA]AA+ (Stable) and [ICRA]A1+.
Total debt instruments covered under this rating action amount to ₹6,250 crore.
The 'Stable' outlook indicates ICRA's expectation of consistent performance and credit metrics.
👀 What to Watch
The reaffirmation of high credit ratings confirms the company's strong balance sheet and low default risk. Investors should view this as a validation of financial stability, requiring no immediate portfolio changes.
Bank of India to Exercise Call Option on 9.30% AT1 Bonds Series VII
Bank of India has announced its decision to exercise the call option for its 9.30% Additional Tier I (AT1) Bonds Series VII. The bank has fixed March 13, 2026, as the record date to identify bondholders eligible for the redemption. The total payment, comprising the principal amount and interest for the broken period, will be disbursed on March 30, 2026. This move is a standard capital management procedure for bonds issued in March 2021 and indicates the bank's stable liquidity position.
Key Highlights
Exercise of call option for 9.30% Additional Tier I Bonds Series VII (ISIN: INE084A08144)
Record date for determining eligible bondholders is March 13, 2026
Full redemption of principal and interest scheduled for March 30, 2026
Bonds were originally issued on March 30, 2021, with a 5-year call option clause
👀 What to Watch
Bondholders should ensure their bank and demat details are updated by March 13, 2026, to receive the redemption proceeds. Equity investors can view this as a routine capital management activity reflecting healthy liquidity.
JNK India Q3 FY26 PAT Surges 534% YoY to ₹180.2 Mn; Revenue Doubles to ₹2,062 Mn
JNK India reported a stellar Q3 FY26 with revenue growing 112.8% YoY to ₹2,062.3 million and PAT jumping 534.1% to ₹180.2 million. The company maintains a robust order book of approximately ₹1,700 crores, supported by domestic projects like BPCL Bina and international prospects like the Dangote refinery expansion. The newly formed JV with Chemdist contributed ₹23 crores in revenue this quarter, signaling progress in green hydrogen and sustainable fuels. Management highlighted a shift in accounting policy to the input method, which is expected to normalize margins moving forward.
Key Highlights
Revenue grew 112.8% YoY to ₹2,062.3 million with an operating profit margin of 27.2%
Net profit (PAT) witnessed a massive 534.1% YoY increase to ₹180.2 million
Order book remains strong at approximately ₹1,700 crores as of January 1, 2026
Subsidiary business (Chemdist JV) contributed ₹23 crores to revenue with a ₹100 crore order book
Management identified significant future opportunities in Nigeria (Dangote refinery) and the Middle East
👀 What to Watch
Investors should view the strong revenue growth and healthy order pipeline as a positive sign of execution capability. Monitor the conversion of the Dangote refinery and Middle East bids as these are key catalysts for future growth.
JNK India Shareholders Approve Material Related Party Transactions; 36% Institutions Dissent
JNK India Limited has received shareholder approval for two material related party transactions (RPT) involving its subsidiary, JNK Chemdist Technologies. The resolutions passed with a 67.6% majority among voting public shareholders, as the promoter group abstained from voting due to being interested parties. While the resolutions were successful, a notable 36.4% of institutional votes were cast against the proposals. These transactions facilitate operational dealings between the parent, its subsidiary, and Chemdist Process Solutions.
Key Highlights
Both resolutions for material related party transactions passed with a 67.62% majority.
Public institutional participation was very high at 99.91%, though 36.40% of their votes were cast against the resolutions.
Promoters and the promoter group, holding 37.9 million shares, did not participate in the voting as interested parties.
The transactions involve JNK Chemdist Technologies Private Limited and Chemdist Process Solutions Private Limited.
A total of 9.91 million votes were polled out of the eligible public shareholding base.
👀 What to Watch
Monitor future financial statements for the actual value and impact of these related party transactions on margins. The significant institutional dissent suggests investors should stay alert to corporate governance and arm's length pricing.
JNK India Q3 FY26 PAT Surges 534% YoY to ₹180.2 Mn; Order Book at ₹17,611 Mn
JNK India delivered a stellar performance in Q3 FY26, with revenue doubling to ₹2,062.3 Mn and PAT growing over six-fold to ₹180.2 Mn. The company's 9M FY26 revenue rose 67.2% YoY to ₹4,934.1 Mn, supported by a robust order book of ₹17,611 Mn which provides strong future visibility. EBITDA margins for the quarter improved significantly to 14.3% from 10.1% in the year-ago period. The company is successfully diversifying its portfolio with the commencement of operations at JNK Chemdist, focusing on sustainable fuels and chemicals.
Key Highlights
Q3 FY26 Revenue grew 112.8% YoY to ₹2,062.3 Mn compared to ₹969.2 Mn in Q3 FY25.
Q3 FY26 PAT skyrocketed 534.3% YoY to ₹180.2 Mn with PAT margins expanding to 8.7%.
Total order book stands at ₹17,611 Mn as of December 31, 2025, with a 9M inflow of ₹11,372 Mn.
Heating solutions remain the core segment, contributing 89.6% of the total order book.
9M FY26 ROCE and ROE reported at 13.6% and 8.3% respectively.
👀 What to Watch
Investors should take note of the massive order book which is nearly 3.5x the 9M revenue, indicating strong growth potential. The significant margin expansion and successful entry into green energy segments through joint ventures make it a compelling growth story in the industrial equipment space.
JNK India Q3 FY26 PAT Jumps 534% YoY to ₹180.3 Mn; Order Book Hits ₹17,611 Mn
JNK India delivered exceptional Q3 FY26 results, with revenue growing 112.8% YoY to ₹2,062.3 million and PAT surging 534.3% to ₹180.3 million. The company's order book remains strong at ₹17,611 million, backed by ₹11,372 million in new inflows during the first nine months of the fiscal year. Profitability showed marked improvement, with EBITDA margins expanding to 14.3% in Q3 from 10.1% in the previous year. The strategic expansion into green hydrogen through the JNK Chemdist joint venture adds a high-growth vertical to its core heating equipment business.
Key Highlights
Q3 FY26 Revenue surged 112.8% YoY to ₹2,062.3 million, while 9M FY26 Revenue rose 67.2% to ₹4,934.1 million.
Net Profit (PAT) for Q3 FY26 skyrocketed by 534.3% YoY to ₹180.3 million.
Total Order Book reached ₹17,611 million as of December 31, 2025, with 89.6% coming from heating solutions.
EBITDA for Q3 FY26 increased by 202.8% YoY to ₹295.1 million, with margins expanding to 14.3%.
Petrochemicals sector accounts for 85.97% of the total order book, indicating high sector concentration.
👀 What to Watch
Investors should view the massive earnings growth and robust order book as strong indicators of future performance, though sector concentration in petrochemicals remains a key monitorable. The successful integration and scaling of the JNK Chemdist venture into green hydrogen could provide a significant long-term valuation re-rating.
JNK India Q3 FY26 Net Profit Surges to ₹184.6M; Revenue Up 92% YoY
JNK India reported a stellar performance for the quarter ended December 31, 2025, with standalone revenue from operations growing 91.7% YoY to ₹1,789.45 million. Net profit witnessed a massive jump to ₹184.58 million compared to just ₹29.10 million in the same quarter last year. For the nine-month period, the company's profit nearly doubled to ₹332.07 million from ₹168.78 million. The company also announced the operationalization of its new subsidiary, JNK Chemdist Technologies, marking an expansion into the process equipment segment.
Key Highlights
Standalone Revenue from Operations grew 91.7% YoY to ₹1,789.45 million in Q3 FY26.
Net Profit for the quarter skyrocketed to ₹184.58 million from ₹29.10 million in Q3 FY25.
Basic EPS increased significantly to ₹3.30 in Q3 FY26 compared to ₹0.53 in the previous year's quarter.
Nine-month revenue reached ₹4,560.83 million, a 60.6% increase over the ₹2,839.11 million recorded in 9M FY25.
The company has successfully utilized ₹2,796.64 million of its IPO proceeds, primarily for working capital requirements.
👀 What to Watch
The company demonstrates robust growth in both top-line and bottom-line, reflecting strong execution in its core fired heaters business. Investors should monitor the scaling of the newly operationalized 'Process Equipment' segment as a potential future growth driver.
JNK India Q3 FY26 Standalone PAT Surges 534% YoY to ₹184.6 Million; Revenue up 92%
JNK India reported a stellar performance for Q3 FY26, with standalone revenue from operations jumping 91.7% YoY to ₹1,789.45 million. The standalone net profit witnessed a massive growth of 534% YoY, reaching ₹184.58 million compared to ₹29.10 million in the corresponding quarter of the previous year. For the nine-month period ended December 2025, the company has already surpassed its full-year FY25 profit, recording a PAT of ₹332.07 million. Additionally, the company operationalized its new subsidiary, JNK Chemdist Technologies, marking its expansion into the process equipment segment.
Key Highlights
Standalone Revenue from Operations grew 91.7% YoY to ₹1,789.45 million in Q3 FY26.
Standalone Profit After Tax (PAT) skyrocketed 534% YoY to ₹184.58 million from ₹29.10 million.
9M FY26 Standalone PAT of ₹332.07 million has already exceeded the full-year FY25 PAT of ₹301.41 million.
Basic EPS for the quarter rose significantly to ₹3.30 from ₹0.53 in the year-ago period.
Utilized ₹2,796.64 million of IPO proceeds as of December 31, 2025, mainly for working capital requirements.
👀 What to Watch
The company demonstrates strong execution capabilities and robust margin expansion, making it a positive outlook for growth-oriented investors. Monitor the performance of the newly operationalized 'Process Equipment' segment for further diversification benefits.
NK Industries Reports Q3 Net Loss of ₹69.55 Lakhs Amid Ongoing ₹937 Crore Legal Claims
NK Industries reported a net loss of ₹69.55 lakhs for the quarter ended December 31, 2025, compared to a loss of ₹14.56 lakhs in the same period last year. Total income remained stagnant at ₹73.38 lakhs, while the company continues to struggle with a severely eroded net worth and accumulated losses of ₹51,103.89 lakhs. The company remains embroiled in significant legal battles, including a ₹937 crore claim related to the NSEL scam and asset attachments under the MPID and PMLA acts. Auditors have issued a qualified opinion, stating they cannot quantify the final financial impact of these sub-judice matters.
Key Highlights
Net Loss widened to ₹69.55 lakhs in Q3 FY26 from ₹14.56 lakhs in Q3 FY25.
Total Income for the quarter was nearly flat at ₹73.38 lakhs compared to ₹71.17 lakhs YoY.
Company faces a massive legal claim of approximately ₹937 crores plus interest related to NSEL recovery proceedings.
Accumulated reserves stand at a deeply negative ₹51,103.89 lakhs, indicating severe financial distress.
Key operational assets including land and machinery remain attached by the ED and Maharashtra Government under PMLA and MPID acts.
👀 What to Watch
Investors should avoid this stock due to its negative net worth, stagnant operations, and massive unresolved legal liabilities that threaten the company's existence. The audit qualifications regarding the inability to quantify potential losses add significant risk.
Mankind Pharma Subsidiary BSV Subjected to 6-Day GST Search and Inspection
The GST Department, Mumbai, conducted a search and inspection operation at Bharat Serums and Vaccines Limited (BSV), a wholly owned subsidiary of Mankind Pharma. The operation took place over six days, from February 3 to February 8, 2026, under Section 67 of the Maharashtra GST Act. The inspection focused on tax payments, input tax credit claims, reconciliation, and refunds. Mankind Pharma has officially stated that the search has resulted in no material impact on the subsidiary's financials or operations.
Key Highlights
Search conducted by Assistant Commissioner of State Tax (Investigation – B), Mumbai
Operation lasted 6 days from February 3 to February 8, 2026
Focus areas included GST tax payments, input tax credit (ITC) reconciliation, and refunds
Management confirms no material impact on BSV's financial or operational activities
BSV is a wholly owned unlisted subsidiary of Mankind Pharma Limited
👀 What to Watch
Investors should monitor for any subsequent tax demand notices or penalties that may arise from this inspection. While the company claims no material impact, any future liability could affect the subsidiary's valuation.
Mankind Pharma Q3 FY26 Revenue Up 11.5% to ₹3,567 Cr; Adjusted EBITDA Margin at 25.9%
Mankind Pharma reported a steady Q3 FY26 with revenue growing 11.5% YoY to INR 3,567 crores, driven by an 11.1% increase in domestic sales and 14% growth in exports. The company's adjusted EBITDA margin stood at 25.9%, while the chronic segment's contribution rose to 36.7% of total sales. Integration of the BSV acquisition showed positive results with double-digit growth, and the company successfully reduced its net debt to INR 4,294 crores. Management highlighted a recovery in volume growth and significant outperformance in cardio and anti-diabetic therapies compared to the market.
Key Highlights
Q3 FY26 revenue increased 11.5% YoY to ₹3,567 crores with an adjusted EBITDA margin of 25.9%.
Chronic therapy contribution rose to 36.7%, with cardio and anti-diabetes growing at 16.7% and 14.4% respectively.
Export revenue for 9M FY26 surged 51% YoY to ₹1,503 crores, supported by EU GMP certification for the Udaipur facility.
Net debt reduced to ₹4,294 crores, bringing the net debt to adjusted EBITDA ratio down to 1.3x.
Domestic PCPM improved to ₹7.2 lakhs from ₹6.5 lakhs on a trailing 12-month basis.
👀 What to Watch
Investors should monitor the continued integration of BSV and the recovery in the acute segment. The stock remains a strong play on the domestic chronic market and expanding export capabilities.
D-Link India Q3 PAT Rises to ₹9.73 Cr; Faces ₹6.11 Cr Customs Demand & Director Resignation
D-Link (India) reported a steady performance for Q3 FY26, with standalone revenue growing 12.7% year-on-year to ₹375.15 crore. Net profit for the quarter saw a marginal increase to ₹9.73 crore, up from ₹9.44 crore in the previous year's corresponding quarter. The company's bottom line was impacted by a one-time provision of ₹1.92 crore related to the implementation of New Labour Codes. Furthermore, the company is contesting a ₹6.11 crore customs demand regarding royalty payments, while Independent Director Ching Chun Yang has resigned effective February 5, 2026.
Key Highlights
Standalone Revenue from operations grew 12.7% YoY to ₹375.15 crore in Q3 FY26.
Net Profit (PAT) for the quarter stood at ₹9.73 crore compared to ₹9.44 crore in Q3 FY25.
Recognized ₹1.92 crore in incremental employee benefit obligations due to the New Labour Codes effective Nov 2025.
Received a customs demand order of ₹6.11 crore (including penalties) related to royalty payments on third-party imports.
Independent Director Ms. Ching Chun Yang resigned from the Board and all committees effective February 5, 2026.
👀 What to Watch
Investors should monitor the legal proceedings regarding the ₹6.11 crore customs demand and the potential impact of higher employee costs under the New Labour Codes. While revenue growth is stable, the marginal profit growth suggests pressure on margins that warrants a cautious outlook.
D-Link India Q3 Revenue Rises 12.7% to ₹375 Cr; Independent Director Resigns
D-Link (India) Limited reported a steady Q3 FY26 with revenue from operations growing to ₹375.15 crore from ₹332.85 crore YoY. The company's Profit Before Tax remained stable at ₹12.99 crore despite a one-time charge of ₹1.92 crore related to the implementation of New Labour Codes. A significant regulatory update involves a customs demand of ₹6.11 crore regarding royalty payments, which the company is currently evaluating for appeal. Additionally, Independent Director Ms. Ching Chun Yang resigned from the board effective February 5, 2026.
Key Highlights
Revenue from operations increased 12.7% YoY to ₹375.15 crore for the quarter ended December 31, 2025.
Profit Before Tax stood at ₹12.99 crore, showing marginal growth over the ₹12.68 crore reported in Q3 FY25.
Recognized incremental employee benefit obligations of ₹1.92 crore due to the New Labour Codes effective November 2025.
Received a customs demand order of ₹6.11 crore (including penalties) related to royalty payments to the parent company.
Independent Director Ms. Ching Chun Yang resigned from the board and all committees effective February 5, 2026.
👀 What to Watch
Investors should monitor the impact of the customs demand appeal and the company's ability to protect margins against rising regulatory and labor costs. The steady revenue growth suggests resilience in the networking products segment.
India Ratings Reaffirms Bank of India’s Infra and Tier 2 Bonds at ‘IND AA+/Stable’
India Ratings has reaffirmed the 'IND AA+/Stable' rating for Bank of India's Infrastructure bonds (₹150 billion) and Tier 2 bonds (₹25 billion). The bank's asset quality has shown significant improvement, with Gross NPA dropping to 2.26% and Net NPA to 0.6% as of 3QFY26. While capital adequacy remains strong at 17.09%, the bank faces pressure on its deposit profile, with the CASA ratio declining to 32.6%. The rating reflects the bank's systemic importance and the high probability of government support given the 73.38% state ownership.
Key Highlights
Reaffirmed 'IND AA+/Stable' rating for ₹150 billion Infrastructure and ₹25 billion Tier 2 bonds
Gross NPA improved to 2.26% in 3QFY26 from 3.27% in FY25; Net NPA stands at a low 0.6%
Capital Adequacy Ratio (CAR) remains healthy at 17.09% with a CET-1 ratio of 13.76%
Return on Assets (RoA) improved to 0.96% in 3QFY26, up from 0.70% in FY24
CASA ratio declined to 32.6%, highlighting ongoing challenges in low-cost deposit mobilization
👀 What to Watch
Investors should take confidence in the improving asset quality and stable credit rating which supports the bank's growth outlook. Monitor the bank's deposit growth and CASA ratio as they remain key areas of competitive pressure.
